Agenus

Yahoo Finance • 2 days ago

Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight

LAS VEGAS, Dec. 1, 2025 /PRNewswire/ -- The colorectal cancer market is growing due to rising incidence driven by aging populations and lifestyle risk factors, which increases demand for screening and treatment. Advances in molecular diagn... Full story

Yahoo Finance • 23 days ago

Agenus reports Q3 results

* Agenus press release [https://seekingalpha.com/pr/20300189-agenus-reports-q3-2025-results-showcasing-clinical-and-regulatory-advances] (AGEN [https://seekingalpha.com/symbol/AGEN]): Q3 GAAP EPS of $1.94. * Revenue of $30.2M (+20.3% Y... Full story

Yahoo Finance • 24 days ago

Earnings week ahead: DIS, CSCO, OXY, PLUG, B, AMAT, JD, BYND, PSKY, and more

[Quarterly report concept.Company financial report.Business charts. Colorful quarter wooden pie chart pieces. Banner with copy space.] Mohamad Faizal Bin Ramli Earnings in the upcoming week will spotlight a diverse lineup across media, te... Full story

Yahoo Finance • 26 days ago

Agenus Q3 2025 Earnings Preview

* Agenus (AGEN [https://seekingalpha.com/symbol/AGEN]) is scheduled to announce Q3 earnings results on Monday, November 10th, before market open. * The consensus EPS Estimate is $2.20 [https://seekingalpha.com/symbol/AGEN/earnings/esti... Full story

Yahoo Finance • 4 months ago

Monday's pre-market session: top gainers and losers

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT E... Full story

Yahoo Finance • 5 months ago

Agenus unit, MiNK surges after peer-reviewed data for lead drug

* Shares of MiNK Therapeutics (NASDAQ:INKT [https://seekingalpha.com/symbol/INKT]) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN [https://seekingalpha.c... Full story

Yahoo Finance • 6 months ago

Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL

[Collaboration concept in word tag cloud] rafal_olechowski Agenus (NASDAQ:AGEN [https://seekingalpha.com/symbol/AGEN]) added ~21% in the premarket on Tuesday after the Massachusetts-based biotech announced a partnership with the Indian ph... Full story

Yahoo Finance • last year

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluat... Full story

Yahoo Finance • last year

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus In a regulatory filing Friday, Agenus Inc (NASDAQ:AGEN) revealed Bristol Myers Squibb & Co (NYSE:BMY) terminated a license, development, and commercialization agr... Full story

Yahoo Finance • 2 years ago

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy The study achieved durable elimination of ctDNA, a critical biom... Full story

Yahoo Finance • 2 years ago

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

growth curve Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. Wi... Full story

Yahoo Finance • 2 years ago

With 52% institutional ownership, Agenus Inc. (NASDAQ:AGEN) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Agenus' stock price is sensitive to their trading actions A total of 12 investors have a majority stake in the company with 51% ownership Analyst forecasts along with ownersh... Full story

Yahoo Finance • 3 years ago

Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

Conference Call on Tuesday, May 9, 2023 at 8:30 a.m. ET LEXINGTON, Mass., April 25, 2023--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, t... Full story

Yahoo Finance • 3 years ago

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced th... Full story

Yahoo Finance • 3 years ago

Agenus (AGEN) Q4 2022 Earnings Call Transcript

Thank you for holding and welcome, everyone, to the Agenus fourth quarter and full year 2022 financial results conference call. This is a very extensive list of difficult-to-treat cancers that have been treated and failed prior treatments.... Full story

Yahoo Finance • 3 years ago

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in... Full story

Yahoo Finance • 3 years ago

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to prese... Full story

Yahoo Finance • 3 years ago

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational... Full story

Yahoo Finance • 3 years ago

2 Momentum Trades Showing Worst to First Action

It seems every January a common theme emerges within my portfolio. Indeed, Real Money's Jonathan Heller creates and tracks a portfolio each year specifically based on this phenomenon. Let's start with small-cap biotech name Agenus Inc. , w... Full story

Yahoo Finance • 3 years ago

Agenus (NASDAQ:AGEN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 42%

Many investors define successful investing as beating the market average over the long term. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to report that long term Agenus Inc. (NASDAQ... Full story